tradingkey.logo

PharmaCyte Biotech Inc

PMCB
查看详细走势图
0.765USD
-0.005-0.68%
收盘 12/24, 13:00美东报价延迟15分钟
5.20M总市值
亏损市盈率 TTM

PharmaCyte Biotech Inc

0.765
-0.005-0.68%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.68%

5天

-7.25%

1月

+17.69%

6月

-27.83%

今年开始到现在

-51.27%

1年

-52.19%

查看详细走势图

TradingKey PharmaCyte Biotech Inc股票评分

单位: USD 更新时间: 2025-12-24

操作建议

PharmaCyte Biotech Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名218/404位。机构持股占比非常高,中期看,股价处于下降通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

PharmaCyte Biotech Inc评分

相关信息

行业排名
218 / 404
全市场排名
410 / 4562
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 0 位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

PharmaCyte Biotech Inc亮点

亮点风险
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
业绩转盈
公司业绩转盈,最新年度盈利美元
估值合理
公司最新PE估值-0.69,处于3年历史合理位
机构减仓
最新机构持股457.38K股,环比减少56.94%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值80.00K
活跃度增加
近期活跃度增加,过去20天平均换手率4.02

PharmaCyte Biotech Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

PharmaCyte Biotech Inc简介

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
公司代码PMCB
公司PharmaCyte Biotech Inc
CEOSilverman (Joshua N)
网址https://pharmacyte.com/

常见问题

PharmaCyte Biotech Inc(PMCB)的当前股价是多少?

PharmaCyte Biotech Inc(PMCB)的当前股价是 0.765。

PharmaCyte Biotech Inc的股票代码是什么?

PharmaCyte Biotech Inc的股票代码是PMCB。

PharmaCyte Biotech Inc股票的52周最高点是多少?

PharmaCyte Biotech Inc股票的52周最高点是1.900。

PharmaCyte Biotech Inc股票的52周最低点是多少?

PharmaCyte Biotech Inc股票的52周最低点是0.630。

PharmaCyte Biotech Inc的市值是多少?

PharmaCyte Biotech Inc的市值是5.20M。

PharmaCyte Biotech Inc的净利润是多少?

PharmaCyte Biotech Inc的净利润为23.36M。

现在PharmaCyte Biotech Inc(PMCB)的股票是买入、持有还是卖出?

根据分析师评级,PharmaCyte Biotech Inc(PMCB)的总体评级为--,目标价格为--。

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是多少

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是-1.116。
KeyAI